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TR-FRET Data
Our investigation of the proposed mechanism of action (i.e that the compounds act by inhibiting FXXLF recruitment to AR through a non-LBP mediated fashion) was informed by following some key points presented in 1 which includes guidelines on the identification of screening artifacts in the drug discovery process. In this case we were particularly interested in excluding an aggregation based mechanism of action especially for 3, which physically manifests as a colloidal solution.
Therefore the TR-FRET assay was adapted by including 0.01% of a nonionic detergent (Triton X-100) in the assay buffer used for compound dilutions and by observing activity after spinning the solution for several minutes in a microfuge. 
